Results 211 to 220 of about 180,170 (299)

Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide

Blood Cancer Journal
Diana Cirstea, Rajib Shome, Mehmet Samur, Srikanth Talluri, Joseph J. Connolly, Alexandra Jean Wright, Emilie Duvallet, Amanda N. R. Joyce, Kathleen Lively, Gina Basinsky, Andrew J. Yee, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul G. Richardson, Noopur S. Raje   +15 more
doaj   +1 more source

Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.

Blood
Du T, Fang T, Pillai S, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC.   +18 more
europepmc   +1 more source

Bone-modifying therapy in multiple myeloma: a comprehensive review. [PDF]

Front Oncol
Bogeljić Patekar M, Milunović V, Mandac Smoljanović I, Bašić Kinda S, Ostojić Kolonić S, Radić-Krišto D, Gašparov S, Baljevic M.   +7 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. [PDF]

J Clin Oncol
Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK.   +15 more
europepmc   +1 more source

Temporal dynamics of immune effector cell‐associated haematotoxicity: Linking early and late cytopenias after chimeric antigen receptor T cells

British Journal of Haematology, EarlyView.
Malvina Bichon, Roch Houot, Mana Alshehri, Guillaume Manson, Faustine Lhomme, Samuel Vic   +5 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Cancer Biology & Medicine
Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao, Zhen Cai   +8 more
doaj   +1 more source

Deciphering epigenetic crosstalk in multiple myeloma pathogenesis and treatment. [PDF]

Clin Epigenetics
Alipoor SD, Shrestha M, Liu A, Chang H.
europepmc   +1 more source

Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL‐Fusion Leukemia

Cancer Science, EarlyView.
Combined SETD2 and menin inhibitors make synergistic effects against MLL‐fusion leukemia; the combination therapy reduces the expression of target genes through blocking transcription elongation and initiation. ABSTRACT During transcriptional elongation, the histone methyltransferase SETD2 binds to RNA polymerase II and deposits trimethylation marks at
Anpei Li, Yuan Zhang, Ziwei Li, Anhao Liu, Li Zhang, Shubin Gao, Xiao Lin, Xiaoming Liu, Huan Li, Guanghui Jin, Bin Xu   +10 more
wiley   +1 more source